Intellia beruft Jing L. Marantz per 26. Oktober 2026 zur Chief Medical Officerin (EVP)

• Intellia Therapeutics ernennt Jing L. Marantz per 26. Oktober 2026 zur Executive Vice President und Chief Medical Officer.
• Marantz leitete zuletzt als Chief Medical Officer bei Scholar Rock die klinische Entwicklung bis zur US-Zulassung von ISEMBYLD.
• Zuvor hatte sie Führungsfunktionen bei Krystal Biotech, Acceleron, Alnylam, Alexion, Biogen, ARIAD und Millennium Pharmaceuticals.
• Als Chief Medical Officer verantwortet sie Translational, Entwicklung, Regulatory sowie Medical Affairs.
• Marantz bleibt Mitglied des Board of Directors von Arcturus Therapeutics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130730PRIMZONEFULLFEED9843270) on October 13, 2026, and is solely responsible for the information contained therein.